Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Peptyde Bio
St. Louis, Missouri, United Statesinvaio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Peptyde Bio developed a technology platform to discover and design novel antimicrobial peptides as environmentally friendly alternatives to chemical fungicides. Their lead AMP provided significant control of gray mold disease in tomatoes during early field testing. The company was acquired by Invaio Sciences in December 2023 to accelerate the development of sustainable crop protection solutions.
- Therapeutic areas
- Other
- Modalities
- PeptidesAntimicrobial peptidesBiologic
- Industry
- Agriculture & AgTech
02
Partnerships
Donald Danforth Plant Science Center/Danforth Technology CompanyInvaio SciencesBioGenerator VenturesWells Fargo Innovation Incubator
Beyond the preview
Go deeper on Peptyde Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptyde Bio.